latest news releases from the newsroom
Direct Edge Daily Volume Surpasses One Billion Shares
JERSEY CITY, N.J., July 14, 2008 (PRIME NEWSWIRE) -- Direct Edge ECN broke its all-time daily volume mark on Friday, July 11, handling 1.05 billion shares. Direct Edge is one of only four U.S. equities trading venues to have ever surpassed the billion share mark in a single day of trading.
Market Pulse Announces its AM Stock Picks for Monday, July 14, 2008: CPST, HYBR, JAVA, AUY
ATLANTA, July 14, 2008 (PRIME NEWSWIRE) -- Market Pulse is pleased to announce the following stock picks. Bernard Schmitt of Market Pulse states, "These particular stocks should be closely watched due to existing fundamental and technical factors affecting each company." Bernard possesses many years of experience in the financial industry evaluating and picking stocks. He rates them as follows:
Travelzoo Launches Summer Deals Section and Proves Summer Travel is Still Affordable
NEW YORK, July 14, 2008 (PRIME NEWSWIRE) -- Travelzoo (Nasdaq:TZOO), a global Internet media company, today revealed the results of a national survey* that showed 4 out of 5 Americans (80 percent) believe the era of affordable travel is over. Although travelers may have a gloomy outlook, travel deals are still abundant. Travelzoo launched a list of summer travel deals that enable travelers to save as much as 60 percent. To find the latest summer travel deals, visit www.travelzoo.com/summerdeals.
Kentucky Energy, Inc.
Quest Minerals & Mining Plans Initial Rehab On Cedar Grove Mine
PATERSON, N.J., July 14, 2008 (PRIME NEWSWIRE) -- Quest Minerals & Mining Corp. (OTCBB:QMNM) (Frankfurt:QMNB), a Kentucky based operator of energy and mineral related properties, is very pleased to announce that its contract mining group, Whitestar Mining, LLC., is in the process of taking the initial steps necessary to open the Cedar Grove mines. Representatives from both Quest and Whitestar plan to convene over the weekend to finalize all terms of the mining agreement.
Penwest Pharmaceuticals Co.
Penwest Begins Phase Ia Clinical Trial of A0001, a Compound For Treatment of Mitochondrial Diseases
DANBURY, Conn., July 14, 2008 (PRIME NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has begun dosing in a Phase Ia clinical trial of A0001, a compound the Company is developing for the treatment of symptoms associated with mitochondrial diseases. Mitochondrial diseases are devastating illnesses that often occur during childhood and currently have no FDA approved treatments.